Arxada invests 20 million Swiss francs in Czech industrial biotechnology plant

KouÅ™im plant upgrades will benefit Arxada’s Contract Development Manufacturing Organization business

Specialty chemicals company Arxada has announced a 20 million Swiss franc investment in its industrial biotechnology plant in Kouřim, Czech Republic.

The facility serves Arxada’s CDMO, or Contract Development Manufacturing Organization, which is part of Arxada’s Specialty Products Solutions business.

The company owned by Bain Capital and Cinven is divided into two segments: Microbial Control Solutions and Specialty Products Solutions, which also includes performance intermediates and chemicals, and composite materials.

Lukas von Hippel, VP CDMO Business Line at Arxada, commented: “Our location in Kouřim is an integral part of our future strategy. Following the implementation of our new strategy in May 2020, we have seen more and more clients request our support in their new projects.

“Our business development team and process development team in KouÅ™im can accelerate development and reduce time to market by over a year in some cases. “

“We are seeing an increasing demand for CDMO projects in the field of biotechnology,” added Zdena Cermakova, manager of the Kouřim site, Arxada.

About Carrie Scheer

Check Also

Food Release Agents Market Expected to Gain Popularity Globally by 2030 – SMU Daily Mustang

the global release agent market size been $697.0 million in 2021and it is expected to …